Vitamin D supplementation for cardiovascular disease prevention.
JAMA The Journal of the American Medical Association (Impact Factor: 29.98). 10/2011; 306(14):1546-7; author reply 1547-8. DOI: 10.1001/jama.2011.1465
Article: Vitamin d and cardiovascular health.Circulation 11/2013; 128(22):2404-6. · 14.95 Impact Factor
- Bioanalysis 03/2014; 6(6):721-3. · 3.25 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: In vitro studies have shown that vitamin D may induce several cytochrome P450 (CYP) enzymes in general and CYP3A4 in particular. The primary aim of this study was to investigate the relationship between plasma levels of 25-hydroxyvitamin D3 and suggested in vivo markers of CYP3A activity in healthy volunteers from Sweden and Korea.Plasma concentrations of 25-hydroxyvitamin D3 were analysed in samples from three previously performed studies, and the correlation between these levels and suggested in vivo markers of CYP3A activity was investigated by means of non-parametric correlation. In addition, we studied the modulating effects of three vitamin D receptor promoter polymorphisms on the association between 25-hydroxyvitamin D3 and CYP3A enzyme activity in Swedish subjects.The plasma levels of 25-hydroxyvitamin D3 were not significantly associated with CYP3A phenotypes in any of the three studies, but after accounting for the vitamin D receptor polymorphism rs4516035, there was a significant positive association between 25-hydroxyvitamin D3 and CYP3A activity (p=0.004). Swedes (n=65) had significantly higher 25-hydroxyvitamin D3 levels than Koreans (n=67), 75 nmol/L compared to 31 nmol/L (p<0.001). Swedish women taking oral contraceptives (OC) (n=19) had somewhat higher plasma levels of 25-hydroxyvitamin D3 compared to Swedish women not taking oral contraceptives (n=21), 89 and 72 nmol/L, respectively (p=0.02).In conclusion, our results suggest that the overall influence on the CYP3A activity by 25-hydroxyvitamin D3 is of marginal importance.This article is protected by copyright. All rights reserved.Basic & Clinical Pharmacology & Toxicology 03/2014; · 2.18 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.